AbCellera Biologics Management

Management criteria checks 4/4

AbCellera Biologics' CEO is Carl Hansen, appointed in Nov 2012, has a tenure of 11.67 years. total yearly compensation is $714.94K, comprised of 64.3% salary and 35.7% bonuses, including company stock and options. directly owns 19.24% of the company’s shares, worth €155.99M. The average tenure of the management team and the board of directors is 3 years and 4.8 years respectively.

Key information

Carl Hansen

Chief executive officer

US$714.9k

Total compensation

CEO salary percentage	64.3%
CEO tenure	11.7yrs
CEO ownership	19.2%
Management average tenure	3yrs
Board average tenure	4.8yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Carl Hansen's remuneration changed compared to AbCellera Biologics's earnings?
Date	Total Compensation	Salary	Company Earnings
Mar 31 2024	n/a	n/a	-US$147m
Dec 31 2023	US$715k	US$460k	-US$146m
Sep 30 2023	n/a	n/a	-US$129m
Jun 30 2023	n/a	n/a	-US$74m
Mar 31 2023	n/a	n/a	-US$50m
Dec 31 2022	US$9m	US$450k	US$159m
Sep 30 2022	n/a	n/a	US$248m
Jun 30 2022	n/a	n/a	US$200m
Mar 31 2022	n/a	n/a	US$205m
Dec 31 2021	US$9m	US$400k	US$153m
Sep 30 2021	n/a	n/a	US$177m
Jun 30 2021	n/a	n/a	US$197m
Mar 31 2021	n/a	n/a	US$203m
Dec 31 2020	US$17m	US$296k	US$85m
Sep 30 2020	n/a	n/a	-US$285k
Jun 30 2020	n/a	n/a	US$2m
Mar 31 2020	n/a	n/a	-US$3m
Dec 31 2019	US$250k	US$177k	-US$2m

Compensation vs Market: Carl's total compensation ($USD714.94K) is below average for companies of similar size in the German market ($USD1.37M).

Compensation vs Earnings: Carl's compensation has been consistent with company performance over the past year.

CEO

Carl Hansen (49 yo)

11.7yrs

Tenure

US$714,939

Compensation

Dr. Carl L. G. Hansen, Ph.D. is a Co-Founder of AbCellera Biologics Inc. and has been its Chief Executive Officer and Director since November 2012 and serves as its Chairperson. Dr. Hansen serves as a Memb...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Carl Hansen	CEO, President & Chairperson	11.7yrs	US$714.94k	19.24% $ 156.0m
Andrew Booth	Chief Financial Officer	4.9yrs	US$674.56k	0.097% $ 782.8k
Veronique Lecault	COO & Director	5.5yrs	US$650.59k	3.27% $ 26.5m
Tryn Stimart	Chief Legal Officer	4.9yrs	US$667.69k	0.00017% $ 1.4k
Marcie Thiessen	Senior Director of Finance & Accounting	no data	no data	no data
Ester Falconer	Chief Technology Officer	3.5yrs	no data	no data
Kathleen Reid	Head of Corporate Communications	less than a year	no data	no data
Graham Craig	Director of Corporate Development	1.5yrs	no data	no data
Murray McCutcheon	Senior Vice President of Partnering	1.5yrs	no data	no data
Neil Aubuchon	Chief Commercial Officer	2.5yrs	US$5.61m	0.016% $ 133.4k
Adam Clarke	Senior Vice President of Discovery	no data	no data	no data
Paul Colussi	Site Head & VP of Complex Membrane Protein Technologies	1.5yrs	no data	no data

3.0yrs

Average Tenure

49.5yo

Average Age

Experienced Management: 8QQ's management team is considered experienced (3 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Carl Hansen	CEO, President & Chairperson	11.7yrs	US$714.94k	19.24% $ 156.0m
Veronique Lecault	COO & Director	5.9yrs	US$650.59k	3.27% $ 26.5m
Michael Hayden	Independent Lead Director	4.8yrs	US$105.00k	0.49% $ 4.0m
John Montalbano	Independent Non-Employee Director	3.7yrs	US$77.50k	0.031% $ 250.9k
Wen-Chaun Lo	Independent Director	2.6yrs	US$55.00k	0% $ 0

4.8yrs

Average Tenure

58yo

Average Age

Experienced Board: 8QQ's board of directors are considered experienced (4.8 years average tenure).

AbCellera Biologics Management

Management criteria checks 4/4

Key information

Recent management updates

AbCellera Biologics Inc., Annual General Meeting, Jun 13, 2024

AbCellera Biologics Inc. Announces Board Changes

DAMONA Pharmaceuticals Appoints John Reilly as Member of the Board of Directors

Chief Financial Officer recently bought €93k worth of stock

CEO, President & Chairperson recently bought €810k worth of stock

CEO, President & Chairperson recently bought €2.3m worth of stock

Recent updates

AbCellera Biologics Inc. to Report Q2, 2024 Results on Aug 06, 2024

First quarter 2024 earnings released: US$0.14 loss per share (vs US$0.14 loss in 1Q 2023)

AbCellera Biologics Inc., Annual General Meeting, Jun 13, 2024

AbCellera Biologics Inc. to Report Q1, 2024 Results on May 07, 2024

AbCellera Announces Four Presentations on T-Cell Engagers at AACR 2024

AbCellera Biologics Inc. Announces Board Changes

AbCellera Biologics Inc. to Report Fiscal Year 2023 Results on Feb 20, 2024

Abcellera Biologics, Inc. Announces Reorganization

AbCellera Presents New Data on Two T-Cell Engager Programs at SITC 2023

Third quarter 2023 earnings released: US$0.099 loss per share (vs US$0.093 profit in 3Q 2022)

AbCellera Biologics Inc. to Report Q3, 2023 Results on Nov 02, 2023

New major risk - Share price stability

Second quarter 2023 earnings released: US$0.11 loss per share (vs US$0.024 loss in 2Q 2022)

AbCellera Announces that the U.S. Patent Trial and Appeal Board Has Denied Berkeley Lights' Request for Rehearing

New major risk - Share price stability

AbCellera Biologics Inc. to Report Q2, 2023 Results on Aug 03, 2023

DAMONA Pharmaceuticals Appoints John Reilly as Member of the Board of Directors

Chief Financial Officer recently bought €93k worth of stock

First quarter 2023 earnings released: US$0.14 loss per share (vs US$0.59 profit in 1Q 2022)

Full year 2022 earnings released: EPS: US$0.56 (vs US$0.56 in FY 2021)

AbCellera Biologics Inc. to Report Fiscal Year 2022 Results on Feb 21, 2023

CEO, President & Chairperson recently bought €810k worth of stock

Investor sentiment deteriorated over the past week

Third quarter 2022 earnings released: EPS: US$0.093 (vs US$0.077 loss in 3Q 2021)

Investor sentiment improved over the past week

AbCellera Biologics Inc. to Report Q3, 2022 Results on Nov 08, 2022

Investor sentiment improved over the past week

CEO, President & Chairperson recently bought €2.3m worth of stock

Investor sentiment improved over the past week

Second quarter 2022 earnings released: US$0.024 loss per share (vs US$0.009 loss in 2Q 2021)

AbCellera Biologics Inc. to Report Q2, 2022 Results on Aug 09, 2022

AbCellera Biologics Inc. Announces Departure of Neil Berkley as Chief Business Officer

CEO, President & Chairperson recently bought €494k worth of stock

Investor sentiment improved over the past week

CEO, President & Chairperson recently bought €453k worth of stock

CEO, President & Chairperson recently bought €8.7m worth of stock

First quarter 2022 earnings released: EPS: US$0.59 (vs US$0.43 in 1Q 2021)

Investor sentiment deteriorated over the past week

AbCellera Biologics Inc. to Report Q1, 2022 Results on May 10, 2022

Investor sentiment improved over the past week

Independent Non-Employee Director recently bought €163k worth of stock

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

AbCellera Biologics Inc. Announces Bebtelovimab Receive Emergency Use Authorization from the U.S. Food and Drug Administration

Investor sentiment improved over the past week

AbCellera Biologics Inc. to Report Q4, 2021 Results on Feb 24, 2022

Investor sentiment deteriorated over the past week

Investor sentiment deteriorated over the past week

President recently bought €2.6m worth of stock

Third quarter 2021 earnings released: US$0.077 loss per share (vs US$0.013 loss in 3Q 2020)

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

AbCellera Biologics Inc. (NasdaqGS:ABCL) acquired TetraGenetics, Inc.

Independent Non-Employee Director recently sold €4.3m worth of stock

Independent Non-Employee Director recently bought €88k worth of stock

Second quarter 2021 earnings released: US$0.009 loss per share (vs US$0.044 profit in 2Q 2020)

Investor sentiment deteriorated over the past week

First quarter 2021 earnings released: EPS US$0.43 (vs US$0.011 in 1Q 2020)

Investor sentiment improved over the past week

Full year 2020 earnings released: EPS US$0.75 (vs US$0.015 loss in FY 2019)

AbCellera-Discovered Bamlanivimab Together with Etesevimab Reduced Hospitalizations and Prevented Death in Phase 3 Trial for Early COVID-19

AbCellera Announces That the European Medicines Agency's Committee for Medicinal Products for Human Use Has Issued A Positive Scientific Opinion for Bamlanivimab Alone and Bamlanivimab Administered Together with Etesevimab

AbCellera Appoints Ester Falconer as Chief Technology Officer

AbCellera-Discoveres Antibody, Bamlanivimab, Administered with Etesevimab Receives FDA Emergency Use Authorization for COVID-19

AbCellera Biologics Inc. to Report Q4, 2020 Results on Mar 29, 2021

Abcellera Biologics Inc. Announces Key Details from the Blaze-2 Study

CEO Compensation Analysis

CEO

Tenure